A5111972058- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Colorectal and Anal Carcinomas
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Gastric Cancer Management and Outcomes
- Neuroendocrine Tumor Research Advances
- Helicobacter pylori-related gastroenterology studies
- Gastrointestinal Tumor Research and Treatment
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Metastasis and carcinoma case studies
- Immunotherapy and Immune Responses
- Immune cells in cancer
- Hedgehog Signaling Pathway Studies
- Cancer Treatment and Pharmacology
- Liver physiology and pathology
- Eosinophilic Esophagitis
- Ferroptosis and cancer prognosis
Université de Versailles Saint-Quentin-en-Yvelines
2016-2025
Université Paris-Saclay
2017-2025
Hôpital Ambroise-Paré
2014-2024
Assistance Publique – Hôpitaux de Paris
2008-2024
CHU Ambroise Paré
2005-2024
Biomarqueurs et essais cliniques en Cancérologie et Onco-Hématologie
2022
Institut Lavoisier de Versailles
2012-2021
Service de la Santé Publique
2021
Laboratoire de Biologie et Pharmacologie Appliquée
2018
Heidelberg University
2013
Most patients with colorectal liver metastases (LMs) receive systemic chemotherapy. This study aimed to determine the significance of a complete response on imaging LMs after chemotherapy.Between 1998 and 2004, 586 were treated for in one institution. Of these, 38 following criteria included study: fewer than 10 before chemotherapy; disappearance or several computed tomography (CT) scan ultrasound; surgery intraoperative ultrasound within 4 weeks imaging; no extrahepatic disease; follow-up...
Immune checkpoint inhibitors, as nivolumab, are used in advanced non-small cell lung cancer (NSCLC). However, no associated biomarker is validated clinical practice with this drug. We investigated herein immune-related blood markers patients NSCLC treated nivolumab. Plasma of 43 consecutive were prospectively collected at time the diagnosis cancer, initiation nivolumab and first tumour evaluation (2 months). Concentrations PD-L1 (sPD-L1), soluble PD-L2 (sPD-L2), Interleukine-2 (sIl-2),...
In Brief Objective: The aim of the study was to evaluate prognostic value ratio metastatic examined lymph nodes (LNR) in patients with rectal cancer. Summary Background Data: Lymph has been shown have colon impact LNR on disease-free and overall survival cancer is unknown. Patients Methods: From 1998 2004, 307 underwent resection for adenocarcinoma. relationships between at 3 years 15 variables, including presence or absence nodes, total number examined, LNR, were analyzed by multivariate...
The prognostic value of BRAF and KRAS mutations in patients who have undergone resection for colon cancer been treated with combination leucovorin, fluorouracil, oxaliplatin (FOLFOX)-based adjuvant chemotherapy is controversial, possibly owing to a lack stratification on mismatch repair status.To examine the effect stage III FOLFOX or without cetuximab.This study included available tumor blocks resected adenocarcinoma participated between December 2005 November 2009 PETACC-8 phase randomized...
The prognostic impact of DNA mismatch repair (MMR) status in stage III colon cancer patients receiving FOLFOX (folinic acid, fluorouracil, and oxaliplatin) adjuvant chemotherapy remains controversial.
Recent data suggested a role of gut microbiota and antibiotic use on immune checkpoint inhibitors efficacy. We aimed to evaluate the impact early (EUA), blood microbiome plasmatic citrulline (marker intestinal barrier) nivolumab efficacy in non-small cell lung cancer (NSCLC).We included all consecutive patients with advanced NSCLC treated our Department between 2014 2017. Blood was analyzed at month (M) M0 M2. Citrulline rates were evaluated M0, M2, M4 M6.Seventy-two (EUA 42%). Overall...
The identification of individuals who should undergo hereditary nonpolyposis colorectal cancer (HNPCC) genetic testing remains a critical issue. Bethesda guidelines were developed to preselect patients for microsatellite instability (MSI) before germline mutation screening. These criteria have been revised, and new set recommendations, the revised guidelines, has proposed.To evaluate performance these identifying with HNPCC in series unselected consecutive compare this guidelines-based...
The primary endpoint was to analyze the predictive factors of lymph node involvement (LN+).Indications for additional right hemicolectomy (RHC) with (LN) resection after appendectomy appendix neuroendocrine tumor (A-NET) remain controversial, especially tumors between 1 and 2 cm in size.National study including all patients nonmetastatic A-NET diagnosed January, 2010 France.In all, 403 were included. A-NETs were: within tip (67%), body (24%) or base (9%) appendix; size < (62%), (30%), >2...
Nivolumab is an anti-PD1 antibody, given in second-line or later treatment advanced non-small cell lung cancer (NSCLC). The objective of this study was to describe the predictive value circulating tumor DNA (ctDNA) on efficacy nivolumab NSCLC. We prospectively included all consecutive patients with NSCLC treated our Department between June 2015 and October 2016. Plasma samples were obtained before first injection at evaluation nivolumab. ctDNA analyzed by Next-Generation Sequencing (NGS),...
Context.—Assessment of BRAF p.V600E mutational status has become necessary for treatment patients with metastatic melanoma. Detection mutation by immunohistochemistry was recently reported in several tumor types.Objective.—To evaluate the interobserver reproducibility detection melanoma.Design.—Immunohistochemistry VE1 antibody performed on melanomas 67 patients. Staining interpretation digital image virtual slides tissue microarrays. The determined 7 pathologists from 3 European...
Abstract Histopathological growth patterns (HGPs) are a reliable, reproducible, and strong prognostic biomarker that can be assessed on haematoxylin eosin‐stained sections of resected colorectal liver metastases (CRLM). Assessment estimates the relative fraction tumour–liver interface for each three patterns; desmoplastic HGP reflects good prognosis. Whether preoperative chemotherapy affects is currently unclear. The present international multicentre study evaluates this in an original...
This study was designed to evaluate prospectively magnetic resonance imaging for the prediction of circumferential resection margin in rectal cancer identify which patient could accurately assess before surgery and patients it not.During a 17-month period, preoperative assessment obtained 38 with mid or low cancer. The agreement pathologic examination analyzed.Overall, agreed histologic 28 (73 percent; kappa = 0.47). In all cases disagreement between pathology, overestimated involvement. For...
In colorectal cancer (CRC), T-cell checkpoint blockade is only effective in patients diagnosed with mismatch repair-deficient (MMR-d) cancers. However, defects Human Leukocyte Antigen (HLA) class I expression were reported to occur most MMR-d CRCs, which would preclude antigen presentation these tumours, considered essential for the clinical activity of this immunotherapeutic modality. We revisited paradox by characterising HLA two independent cohorts CRC. determined that loss occurred...
BACKGROUND To validate pathologic markers of response to preoperative chemotherapy as predictors disease‐free survival (DFS) after resection colorectal liver metastases (CLM). METHODS One hundred seventy‐one patients who underwent CLM at 4 centers were studied. Pathologic response—defined the proportion tumor cells remaining (complete, 0%; major, <50%; minor, ≥50%) and thickness tumor‐normal interface (TNI) (<0.5 mm, 0.5 <5 ≥5 mm)—was assessed by a central pathology reviewer local...
Background Despite prolonged tumor response to immune checkpoint inhibitors (ICIs) for a subset of patients with advanced non-small cell lung cancer (NSCLC), secondary resistance will occur majority these patients. The understanding late progression mechanisms ICIs is important improve future treatment strategies. Methods We performed whole-exome sequencing (WES) on circulating DNA and compared molecular profiles between the beginning ICI in NSCLC treated who had initial progression, after...
Most of advanced non-small cell lung cancer (NSCLC) patients will experience tumor progression with immunotherapy (IO). Preliminary data suggested an association between high plasma HGF levels and poor response to IO in NSCLC. Our study aimed evaluate further the role HGF/MET pathway resistance We included retrospectively 82 consecutive NSCLC from two academic hospitals. Among them, 49 received ICIs alone or combination chemotherapy (CT), while 33 as control group. analyzed by ELISA...